IL1RL2 and triple-A syndrome: IL‐38 may protect against AAA formation by regulating the accumulation and phenotype of macrophage through IL1RL2‐p38 pathway, therefore, it is speculated that IL‐38 may be a new therapeutic modality for the treatment of AAA.33